Relief Therapeutics Holding AG (RLFTF)

[changes_iv]

Two top FDA vaccine regulators RESIGN 'in fury at White House' for 'politicizing' COVID boosters by announcing third shots for all before the agency gave medical approval

https://www.dailymail.co.uk/news/article-9947445/amp/Two-FDA-vaccine-regulators-RESIGN-clashing-WH-COVID-boosters.html

But the current system for handling COVID-related claims is different – and not in a good way. Because if you’ve suffered an injury related to the Pfizer, Moderna or Johnson & Johnson vaccines, you’re basically out of luck. ———

As Renée Gentry, director of the Vaccine Injury Litigation Clinic at the George Washington University Law School put it, COVID vaccine claimants have two rights: “You have the right to file,” she said. “And you have the right to lose.”

https://www.reuters.com/legal/government/black-hole-covid-vaccine-injury-claims-2021-06-29/

Also, Moss added that many of the nurses and medical professionals are now talking about the mu variant, stating that the vaccine is even less effective against that variant of COVID-19. ———

“Sometimes, they are labeled as anti-vaxxers, and that is not really the case at all. They have had their vaccines from all the other things that were required of them at the hospital, but they have some concerns about this particular vaccine. They’re just asking that we try and delay its implementation for the mandation [sic],” said Del. Amy Summers, R–Taylor County.

https://www.wboy.com/news/health/coronavirus/wvu-medicine-employees-hold-meeting-with-local-state-leaders-regarding-covid-19-vaccination-mandate/

IF THERE IS A RISK OF HARM THERE SHOULD BE CHOICE IN THE MATTER

https://rumble.com/vmgydn-wvuh-to-require-all-employees-to-be-vaccinated-or-will-face-voluntary-termi.html

John Stokes, a Division I Athlete and Academic Medal of Honor student at Tennessee State University, is hospitalized with myocarditis after second jab. John says NCAA should not mandate student athletes get vaccinated due to the high risk of heart issues.

https://www.tiktok.com/@john.stokes/video/7005038789269802245


In the coronary arterial walls, VIP may contribute to the regulation of normal coronary vasomotor tone. In research animals and in humans, VIP, administered into the coronary artery or intravenously, increases the epicardial coronary artery cross-sectional area, decreases coronary vascular resistance, and significantly increases coronary artery blood flow. High frequency parasympathetic (vagal) nerve stimulation also releases endogenous VIP in the coronary vessels and heart and significantly increases coronary artery blood flow. In addition, the release of VIP in the heart is increased during coronary artery occlusion and during reperfusion where VIP may promote local blood flow and may have a free-radical scavenging effect. VIP also has a primary positive inotropic effect on cardiac muscle that is enhanced by its ability to facilitate ventricular-vascular coupling by reducing mean arterial pressure by 10-15%. In concentrations of 10(-8)-10(-5) mol, VIP augments developed isometric force and increases atrial and ventricular contractility. The presence of VIP-immunoreactive nerve fibers in and around the sinus and the atrioventricular nodes of mammals strongly suggests that this peptide can affect the heart rate. In this regard, endogenously released or exogenous VIP can significantly increase the heart rate and has a more potent effect on heart rate than does norepinephrine. The presence and significant cardiovascular effects of VIP in the heart suggests that this peptide is important in the regulation of coronary blood flow, cardiac contraction, and heart rate. Current investigations are defining the physiological role of VIP in the regulation of cardiovascular function.

https://www.researchgate.net/publication/12206497_Vasoactive_intestinal_peptide_Cardiovascular_effects

The global cardiovascular drugs market is expected to be around US$ 90.50 Bn by 2025 CAGR of over 1.0% from 2019 to 2025.

https://www.marketwatch.com/press-release/cardiovascular-drugs-market-share-size-growth-key-companies-cagr-status-by-2028-2021-06-07